
    
      The research program will have two parts:

      Stage1: identification of patients with moderate, high and very high cardiovascular risks,
      not having diseases of atherosclerotic genesis and requiring lipid-lowering drugs.

      Stage 2: a prospective observation of patients receiving primary medical prophylaxis of CVD
      with atorvastatin
    
  